Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.73 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.73 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.73 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.73 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3541911 | 0.85 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11RPS6KB1 | |
| SCHEMBL3550112 | 0.84 | MAPK14 (0.79) | MAPK14MAPK13MAPK12MAPK11RPS6KB1 | |
| SCHEMBL3549101 | 0.83 | MAPK14 (0.77) | MAPK14MAPK13MAPK12MAPK11RPS6KB1 | |
| SCHEMBL3544772 | 0.83 | MAPK14 (0.77) | MAPK14MAPK13MAPK12MAPK11RPS6KB1 | |
| SCHEMBL3542487 | 0.82 | MAPK14 (0.75) | MAPK14MAPK13MAPK12MAPK11RPS6KB1 | |
| SCHEMBL3555008 | 0.82 | MAPK14 (0.72) | MAPK14MAPK13MAPK12MAPK11RPS6KB1 | |
| SCHEMBL3545490 | 0.81 | MAPK14 (0.74) | MAPK14MAPK13MAPK12MAPK11RPS6KB1 | |
| SCHEMBL3542618 | 0.81 | MAPK14 (0.74) | MAPK14MAPK13MAPK12MAPK11RPS6KB1 | |
| SCHEMBL3548752 | 0.79 | MAPK14 (0.68) | MAPK14MAPK13MAPK12MAPK11RPS6KB1 | |
| SCHEMBL3546112 | 0.78 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167247-A1 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. | 2006-07-27 | — | — | US | claimed |
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-04-27 | — | — | US | disclosed |
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-04-27 | — | — | US | disclosed |
| WO-2021138434-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2021-07-08 | — | — | WO | disclosed |
| US-7741479-B2 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741479-B2 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20060167247-A1 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | MAPK14 1913/4885MAPK13 2159/4885MAPK12 1997/4885 |
| US-20060167247-A1 | Urea inhibitors of MAP kinases | MAPK1, MAP3K1, MAP3K20 | MAPK14 47/4885MAPK13 52/4885MAPK12 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.